Monica Benavidez, DO
Psychiatry · Phoenix, AZNPI 1710182225
Payments from drug & device makers
Across 1,287 payments — averaging $337.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$240K
- E.r. Squibb & Sons, L.L.C.$95K
- Alkermes, Inc.$92K
- Johnson & Johnson$2K
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- plus $3K from 6 others
What the payments were for
- Consulting fees$16,5944%
- Speaking & faculty fees$318,04473%
- Travel & lodging$72,23917%
- Food & beverage$27,5936%
- Education$2590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 428 | $239,775 |
| E.r. Squibb & Sons, L.L.C. | 166 | $95,084 |
| Alkermes, Inc. | 267 | $91,701 |
| Johnson & Johnson | 132 | $2,185 |
| Neurocrine Biosciences, Inc. | 51 | $1,523 |
| Otsuka America Pharmaceutical, Inc. | 80 | $1,502 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 61 | $1,255 |
| Indivior Inc. | 40 | $586 |
| Sunovion Pharmaceuticals Inc. | 32 | $384 |
| AbbVie(2 entities) | 16 | $383 |
| Vanda Pharmaceuticals Inc. | 13 | $331 |
| Servier Pharmaceuticals LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$342,207
- UZEDY$231,623
- COBENFY$84,827
- ARISTADA$4,766
- Austedo XR$1,491
- ARISTADA INITIO$1,192
- INGREZZA$590
- AUSTEDO$504
- CAPLYTA$368
- ABILIFY MAINTENA$336
- SPRAVATO$324
- Fanapt$125
- REXULTI$116
- INVEGA TRINZA$102
- INVEGA SUSTENNA$102
How this compares
$434,729 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UzedyRisperidone | 83 | $526,539 |
| AristadaAripiprazole Lauroxil | 101 | $345,214 |
| LybalviOlanzapine/Samidorphan Malate | 301 | $287,160 |
| IngrezzaValbenazine Tosylate | 14 | $104,780 |
| Invega SustennaPaliperidone Palmitate | 27 | $91,593 |
| CaplytaLumateperone Tosylate | 13 | $20,498 |
| Clozapine | 266 | $11,067 |
| Divalproex Sodium ErDivalproex Sodium | 201 | $5,493 |
| Haloperidol Decanoate | 108 | $5,169 |
| Lurasidone Hcl | 58 | $4,032 |
| Trazodone Hcl | 279 | $2,585 |
| Benztropine Mesylate | 207 | $2,555 |
| Fluphenazine Hcl | 20 | $2,416 |
| Quetiapine Fumarate | 120 | $1,906 |
| Bupropion XlBupropion Hcl | 116 | $1,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Lybalvi | $91,701 | $632,374402 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $239,775 | $526,53983 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,523 | $104,78014 claims |
| Johnson & JohnsonInvega Sustenna | $2,185 | $91,59327 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,255 | $20,49813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Phoenix
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Ahmed ElmaadawiPhoenix$395K
- Lee KelleyPhoenix$340K
- Eric ReimanPhoenix$160K
- John PraterPhoenix$101K
- Pallavi JoshiPhoenix$62K
- Padma AkingPhoenix$44K
- Amnon KahanePhoenix$18K
- Mona AminiPhoenix$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.